AU3460897A - Medicinal compositions - Google Patents

Medicinal compositions

Info

Publication number
AU3460897A
AU3460897A AU34608/97A AU3460897A AU3460897A AU 3460897 A AU3460897 A AU 3460897A AU 34608/97 A AU34608/97 A AU 34608/97A AU 3460897 A AU3460897 A AU 3460897A AU 3460897 A AU3460897 A AU 3460897A
Authority
AU
Australia
Prior art keywords
medicinal compositions
medicinal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34608/97A
Inventor
Kenji Chiba
Tsuneo Fujii
Rumiko Kuma
Tadashi Mishina
Atsushi Sakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welfide Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfide Corp filed Critical Welfide Corp
Publication of AU3460897A publication Critical patent/AU3460897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
AU34608/97A 1996-07-18 1997-07-15 Medicinal compositions Abandoned AU3460897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18938096A JP2002241272A (en) 1996-07-18 1996-07-18 Medicinal composition
JP8-189380 1996-07-18
PCT/JP1997/002448 WO1998003162A1 (en) 1996-07-18 1997-07-15 Medicinal compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU18911/99A Division AU1891199A (en) 1996-07-18 1999-01-19 Medicinal compositions

Publications (1)

Publication Number Publication Date
AU3460897A true AU3460897A (en) 1998-02-10

Family

ID=16240353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34608/97A Abandoned AU3460897A (en) 1996-07-18 1997-07-15 Medicinal compositions

Country Status (3)

Country Link
JP (1) JP2002241272A (en)
AU (1) AU3460897A (en)
WO (1) WO1998003162A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002324026B2 (en) * 1996-07-18 2005-07-14 Novartis Ag Pharmaceutical compositions

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209277A (en) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP0990440B1 (en) * 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
JP4627356B2 (en) 1999-06-30 2011-02-09 松森  昭 Drugs for preventing or treating viral myocarditis
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
HUE028247T2 (en) * 2003-04-08 2016-12-28 Novartis Ag Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
JP4838497B2 (en) * 2004-04-09 2011-12-14 キッセイ薬品工業株式会社 Pharmaceutical composition for prevention or treatment of rejection after liver transplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58148816A (en) * 1982-02-27 1983-09-05 Nippon Zenyaku Kogyo Kk Low irritant thiamulin injection
TW200402B (en) * 1990-08-13 1993-02-21 Senju Pharma Co
JPH0616547A (en) * 1992-07-01 1994-01-25 Wakamoto Pharmaceut Co Ltd Antiphlogistic ophthalmic solution
KR0155015B1 (en) * 1992-10-21 1998-12-01 고우야 마사시 2-amino-1,3-propanediol compound and immunosuppressant
JPH07228532A (en) * 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd Water-soluble solution, method for improving solubility of its active ingredient and stabilization thereof
JPH07316065A (en) * 1994-05-25 1995-12-05 Fujisawa Pharmaceut Co Ltd Pharmaceutical preparation of fr 901469 substance
PT778263E (en) * 1994-08-22 2002-06-28 Mitsubishi Pharma Corp COMPOSITION OF BENZENE AND ITS PHARMACEUTICAL UTILIZATION
JPH08175985A (en) * 1994-12-26 1996-07-09 Lion Corp Ophthalmic solution
ATE279185T1 (en) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DI L CONTAINING MEDICINAL PRODUCT FOR TOPICAL USE FOR THE TREATMENT OF DISEASES CAUSED BY A DISRUPTION OF THE IMMUNE SYSTEM

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002324026B2 (en) * 1996-07-18 2005-07-14 Novartis Ag Pharmaceutical compositions

Also Published As

Publication number Publication date
WO1998003162A1 (en) 1998-01-29
JP2002241272A (en) 2002-08-28

Similar Documents

Publication Publication Date Title
AU4762797A (en) Pharmaceutical compositions
AU5136998A (en) Medicinal composition
AU2967597A (en) Pharmaceutical compositions
AU6513298A (en) Therapeutic compositions
AUPN411195A0 (en) Medicinal composition
AU3777897A (en) Pharmaceutical compositions
AU8107998A (en) Pharmaceutical compositions
AU5317598A (en) Novel pharmaceutical compositions
AU5157898A (en) Hnf3delta compositions
GB9610359D0 (en) Pharmaceutical compositions
AU2531295A (en) Pharmaceutical composition
AU9343098A (en) Pharmaceutical composition
AU3460897A (en) Medicinal compositions
ZA979726B (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
AU4326197A (en) Pharmaceutical compositions
AU4457597A (en) Pharmaceutical compositions
AUPN862596A0 (en) Pharmaceutical compositions
AU1544195A (en) Pharmaceutical compositions
AU1427895A (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
AU2896897A (en) Oral pharmaceutical compositions
AU3452997A (en) Vaccine compositions
AUPN876196A0 (en) Medicinal composition